Cart

0

Business

“Johnson & Johnson forecasts as much as 6% sales growth in 2024”

Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara…

The company expects full-year adjusted operational profit of $10.55 to $10.75 per share in 2024, including a 15-cent impact from its recent acquisition of private medical device maker Laminar.

J&J’s 2024 revenue growth forecast excludes sales of its Covid vaccine…”

https://www.cnbc.com/2023/12/05/johnson-johnson-forecasts-as-much-as-6percent-sales-growth-in-2024.html

See the bold? Lawsuits are coming. It’s probably not a good idea to have a wait and see attitude for this stock.

Leave a Reply